Publications by authors named "W H Dillmann"

Emerging evidence indicates the critical roles of microbiota in mediating host cardiac functions in ageing, however, the mechanisms underlying the communications between microbiota and cardiac cells during the ageing process have not been fully elucidated. Bacterial DNA was enriched in the cardiomyocytes of both ageing humans and mice. Antibiotic treatment remarkably reduced bacterial DNA abundance in ageing mice.

View Article and Find Full Text PDF

Sustained hyperglycemia results in excess protein -GlcNAcylation, leading to vascular complications in diabetes. This study aims to investigate the role of -GlcNAcylation in the progression of coronary microvascular disease (CMD) in inducible type 2 diabetic (T2D) mice generated by a high-fat diet with a single injection of low-dose streptozotocin. Inducible T2D mice exhibited an increase in protein -GlcNAcylation in cardiac endothelial cells (CECs) and decreases in coronary flow velocity reserve (CFVR, an indicator of coronary microvascular function) and capillary density accompanied by increased endothelial apoptosis in the heart.

View Article and Find Full Text PDF
Article Synopsis
  • Obesity increases the risk of hypertension by causing a breakdown in gut barriers that allows gut-derived microbiota products, like microbial DNA, to enter the bloodstream and affect organs such as the adrenal glands.
  • * In obese mice, there is a significant buildup of bacterial DNA in the adrenal glands, along with heightened inflammation, while lean mice are protected from this due to the expression of a receptor (CRIg) that blocks gut-derived extracellular vesicles.
  • * Restoring the protective CRIg+ cell population in obese mice reduces microbial DNA levels, inflammation, and hypertension, highlighting the pathogenic role of gut microbiota in obesity-related adrenal dysfunction.
View Article and Find Full Text PDF

Background And Purpose: Heart failure is associated with high morbidity and mortality, and new therapeutic targets are needed. Preclinical data suggest that pharmacological activation of protein kinase G (PKG) can reduce maladaptive ventricular remodelling and cardiac dysfunction in the stressed heart. However, clinical trial results have been mixed and the effects of long-term PKG activation in the heart are unknown.

View Article and Find Full Text PDF